Researchers at the Seoul National University have discovered a new therapeutic target for lung cancer.
It was found that a variant of the protein AIMP2 is highly expressed in lung cancer cells and also that patients demonstrating high expression of this variant showed lower survival.
AIMP2-DX2 compromises the tumor-suppressing activity of AIMP2 by competitively binding to p53.
It was also shown that suppression of AIMP2-DX2 slowed tumor growth, suggesting that this could be an exciting new therapeutic target.
The findings could create an opportunity to develop new innovative cancer drugs, as well as presenting a new target that could also be applied to other cancers.
The study has been published in the open-access journal PLoS Genetics.